Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Deals

Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal

Fineline Cube Jan 22, 2026
Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Fineline Cube Jan 20, 2026
Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Fineline Cube Jan 20, 2026
Company Deals Medical Device

EasyDiagnosis Bio to Acquire 51% of Ailex Medical in $5.1M Deal, Gains IVD Platform

Fineline Cube Jan 20, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Fineline Cube Jan 22, 2026
Company Drug

Boehringer Ingelheim Initiates Phase III FIBRONEER Studies for PDE4B Inhibitor BI 1015550

Fineline Cube Mar 23, 2023

German pharmaceutical giant Boehringer Ingelheim (BI) has announced the first patient enrollments in the Phase...

Company

Grand Pharmaceutical Group Reports 15.1% Revenue Growth in 2022 Financials

Fineline Cube Mar 23, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) published its 2022 financials, reporting revenues of HKD...

Company

Ascentage Pharma’s 2022 Revenue Soars with Olverembatinib Sales

Fineline Cube Mar 23, 2023

China-based Ascentage Pharma (HKG: 6855) has announced its 2022 financial results, marking the first year...

Company Digital

Ping An Good Doctor Reports Revenue Decline but Medical Services Growth in 2022

Fineline Cube Mar 23, 2023

China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as Ping An...

Company Digital

JD Healthcare Reports 52.3% Revenue Growth in 2022 Financial Report

Fineline Cube Mar 23, 2023

JD Healthcare, a unit of China’s e-commerce giant JD.com (NASDAQ: JD), released its 2022 financial...

Company

WuXi Biologics Reports 48.4% Revenue Growth in 2022 Financial Report

Fineline Cube Mar 23, 2023

China-based WuXi Biologics (HKG: 2269) released its 2022 financial report for the period ending December...

Company Drug

Advenchen Lab’s AL8326 and Hengrui’s SHR-A1811 Receive Breakthrough Therapy Designations

Fineline Cube Mar 22, 2023

The Center for Drug Evaluation (CDE) website indicates that Advenchen Lab’s AL8326 and Hengrui Pharmaceuticals’...

Company Deals

Merck & Peking University Launch Public Health Training Projects for Young and Middle-Aged Talent

Fineline Cube Mar 22, 2023

Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) and the Peking University School of Public...

Company Drug

Biokin’s BL-B01D1 Receives NMPA Approval for Phase II Solid Tumor Study

Fineline Cube Mar 22, 2023

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has received approval...

Company Drug

Junshi Biosciences’ JS010 Receives NMPA Approval for Migraine Clinical Trials

Fineline Cube Mar 22, 2023

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that it has received clinical trial...

Company Drug

Immunotech Biopharm’s CAR-T-19-D2 Receives NMPA Approval for DLBCL Clinical Trial

Fineline Cube Mar 22, 2023

China-based chimeric antigen receptor T-cell (CAR-T) specialist Immunotech Biopharm Ltd (HKG: 6978) has announced that...

Company Deals

Smith & Nephew Partners with MedMotion for Digital Health Innovation

Fineline Cube Mar 22, 2023

UK-based Smith & Nephew Plc has announced a strategic partnership with China’s Shanghai Fudong Medical...

Company Deals

Aidea Pharma and China Meheco Partner to Expand Medical and Pharmaceutical Services

Fineline Cube Mar 22, 2023

China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced a partnership with China Meheco...

Company

3SBio Inc. Reports 7.5% Revenue Growth in 2022 Financials

Fineline Cube Mar 22, 2023

China-based 3SBio Inc. (HKG: 1530) released its 2022 financial report, recording revenues of RMB 6.859...

Company Deals

Joincare Pharmaceutical Acquires Rights to TaiGen’s PA Endonuclease Inhibitor TG-1000

Fineline Cube Mar 22, 2023

China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced a licensing agreement with...

Company Drug

Reistone Biopharma’s Ivarmacitinib Shows Positive Results in Phase III QUARTZ3 Study

Fineline Cube Mar 22, 2023

Reistone Biopharma Co., Ltd, incubated by Hengrui Pharmaceuticals (SHA: 600276) with USD 100 million in...

Company Deals

Sinopharm Forms Joint Ventures with Foreign Medical Equipment Firms

Fineline Cube Mar 22, 2023

Sinopharm China National Biotech Group Co., Ltd (CNBG) has announced partnerships with two foreign medical...

Company

BeiGene Marks Topping Off of New Biologics Facility in New Jersey

Fineline Cube Mar 22, 2023

China-based biotech BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) held a ceremony to mark the...

Company Deals Digital

Roche Partners with China Resource Medicine to Promote Xofluza in China

Fineline Cube Mar 22, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has entered into a partnership with China-based China Resource...

Company Deals

Jacobio Pharma Partners with Merck to Evaluate CD73 mAb and Keytruda Combination

Fineline Cube Mar 22, 2023

China-based Jacobio Pharma (HKG: 1167) has announced a clinical partnership with Merck, Sharp & Dohme...

Posts pagination

1 … 493 494 495 … 612

Recent updates

  • Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal
  • Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors
  • Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific
  • Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback
  • Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Company Drug

Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific

Company Drug

Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.